MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Search

Boston Scientific Corp.

Uždarymo kaina

SektoriusSveikatos priežiūra

88.04 -0.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

88.09

Max

88.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4B

2.2B

Pardavimai

4M

5.1B

P/E

Sektoriaus vid.

51.187

90.831

Pelnas, tenkantis vienai akcijai

0.75

Pelno marža

43.87

Darbuotojai

53,000

EBITDA

-341M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+42.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-7.1B

142B

Ankstesnė atidarymo kaina

88.14

Ankstesnė uždarymo kaina

88.04

Naujienos nuotaikos

By Acuity

61%

39%

298 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Boston Scientific Corp. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-15 13:29; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

2026-01-15 12:35; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

2026-01-15 12:29; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

2025-10-22 11:00; UTC

Uždarbis

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

2026-01-15 14:37; UTC

Karštos akcijos

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

2026-01-15 13:45; UTC

Įsigijimai, susijungimai, perėmimai

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

2026-01-15 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

2026-01-15 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

2026-01-15 12:01; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

2026-01-15 12:00; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

2026-01-15 12:00; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

2026-01-12 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

2026-01-12 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

2026-01-12 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

2026-01-12 12:00; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

2025-11-18 17:06; UTC

Uždarbis

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

2025-11-18 12:01; UTC

Uždarbis

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

2025-10-30 12:38; UTC

Uždarbis

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025-10-30 12:01; UTC

Uždarbis

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025-10-22 10:32; UTC

Uždarbis

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

2025-10-22 10:32; UTC

Uždarbis

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

2025-10-22 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

2025-10-22 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Sales Up About 20% >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Adj EPS 75c >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q Sales $5.07B >BSX

2025-10-22 10:30; UTC

Uždarbis

Boston Scientific 3Q EPS 51c >BSX

Akcijų palyginimas

Kainos pokytis

Boston Scientific Corp. Prognozė

Kainos tikslas

By TipRanks

42.82% į viršų

12 mėnesių prognozė

Vidutinis 125.78 USD  42.82%

Aukščiausias 140 USD

Žemiausias 112 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Boston Scientific Corp. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

20

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.95 / 104.93Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

298 / 361 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat